| 000 | 01692 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250518091417.0 | ||
| 264 | 0 | _c20210902 | |
| 008 | 202109s 0 0 eng d | ||
| 022 | _a1573-0646 | ||
| 024 | 7 |
_a10.1007/s10637-020-00918-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aViglietta, Vissia | |
| 245 | 0 | 0 |
_aPhase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients. _h[electronic resource] |
| 260 |
_bInvestigational new drugs _c10 2020 |
||
| 300 |
_a1463-1471 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHealthy Volunteers |
| 650 | 0 | 4 |
_aHearing Loss _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjection, Intratympanic |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aThiosulfates _xadministration & dosage |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aShi, Fuxin | |
| 700 | 1 | _aHu, Qi-Ying | |
| 700 | 1 | _aRen, Yong | |
| 700 | 1 | _aKeilty, John | |
| 700 | 1 | _aWolff, Heather | |
| 700 | 1 | _aMcCarthy, Ryan | |
| 700 | 1 | _aKropp, Jason | |
| 700 | 1 | _aWeber, Pete | |
| 700 | 1 | _aSoglia, John | |
| 773 | 0 |
_tInvestigational new drugs _gvol. 38 _gno. 5 _gp. 1463-1471 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10637-020-00918-1 _zAvailable from publisher's website |
| 999 |
_c30728072 _d30728072 |
||